Acurx says FDA conditionally accepts CIFBEZY brand name for ibezapolstat

PUBT · 2d ago
Acurx says FDA conditionally accepts CIFBEZY brand name for ibezapolstat
  • Acurx won FDA conditional acceptance for CIFBEZY as the proposed brand name for its lead antibiotic candidate ibezapolstat.
  • USPTO allowed the CIFBEZY trademark application, supporting future commercialization plans tied to a potential NDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608170801PR_NEWS_USPR_____NY27012) on August 17, 2026, and is solely responsible for the information contained therein.